Celalettin Ustun to Biosimilar Pharmaceuticals
This is a "connection" page, showing publications Celalettin Ustun has written about Biosimilar Pharmaceuticals.
Connection Strength
0.709
-
Biosimilar infliximab administration for the management of acute graft-versus-host disease. J Oncol Pharm Pract. 2020 Dec; 26(8):2047-2051.
Score: 0.709
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.